

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC2/17 - Immunohistochemistry - Detection of HER-2/neu

Dead line: 05.12.2017

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group		N	Result	N _{rel}
(601) A1 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	5	Weak positivity	11 %
		>	6	Strong positivity	13 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	9	Weak positivity	20 %
		>	2	Strong positivity	4,4 %
	(804) Ventana PATHWAY anti-HER-2/neu		1	Negative (1)	2,2 %
		>>>	19	Weak positivity	42 %
		>	2	Strong positivity	4,4 %
	(999) another manufacturer	>>>	1	Weak positivity	2,2 %
Total per sample: n = 45			Success: 98 %		
Total success: 98 %					
(602) A2 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	11	Negative (0)	24 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11	Negative (0)	24 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22	Negative (0)	49 %
	(999) another manufacturer	>>>	1	Negative (0)	2,2 %
Total per sample: n = 45			Success: 100 %		
Total success: 100 %					
(603) A3 expression HER-2/neu					
Slide	(802) Dako HercepTest		1	Negative (1)	2,2 %
		>>>	9	Weak positivity	20 %
		>	1	Strong positivity	2,2 %
	(803) Dako c-erbB-2 Onkoprotein		1	Negative (1)	2,2 %
		>>>	9	Weak positivity	20 %
		>	1	Strong positivity	2,2 %
	(804) Ventana PATHWAY anti-HER-2/neu		2	Negative (1)	4,4 %
		>>>	20	Weak positivity	44 %
	(999) another manufacturer		1	Negative (1)	2,2 %
Total per sample: n = 45			Success: 89 %		
Total success: 89 %					
(606) B1 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	11	Negative (0)	24 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11	Negative (0)	24 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22	Negative (0)	49 %
	(999) another manufacturer	>>>	1	Negative (0)	2,2 %
Total per sample: n = 45			Success: 100 %		
Total success: 100 %					
(607) B2 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	7	Weak positivity	16 %
		>	4	Strong positivity	8,9 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	10	Weak positivity	22 %
		>	1	Strong positivity	2,2 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	20	Weak positivity	44 %
		>	2	Strong positivity	4,4 %
	(999) another manufacturer	>>>	1	Weak positivity	2,2 %
Total per sample: n = 45			Success: 100 %		
Total success: 100 %					
(608) B3 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	11	Strong positivity	24 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11	Strong positivity	24 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	22	Strong positivity	49 %
	(999) another manufacturer	>>>	1	Strong positivity	2,2 %
Total per sample: n = 45			Success: 100 %		
Total success: 100 %					
(611) C1 expression HER-2/neu					
Slide	(802) Dako HercepTest		1	Negative (1)	2,2 %
		>>>	10	Weak positivity	22 %
	(803) Dako c-erbB-2 Onkoprotein		1	Negative (1)	2,2 %
		>>>	10	Weak positivity	22 %
	(804) Ventana PATHWAY anti-HER-2/neu		2	Negative (1)	4,4 %
		>>>	20	Weak positivity	44 %
	(999) another manufacturer	>>>	1	Weak positivity	2,2 %
Total per sample: n = 45			Success: 91 %		

Test

Sample	Group	N	Result	N _{rel}
Total success: 91 %				
(612) C2 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>> 11	Strong positivity	24 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 11	Strong positivity	24 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>> 22	Strong positivity	49 %
	(999) another manufacturer	>>> 1	Strong positivity	2,2 %
Total per sample: n = 45 Success: 100 %				
Total success: 100 %				
(613) C3 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>> 8	Weak positivity	18 %
		> 3	Strong positivity	6,7 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 9	Weak positivity	20 %
		> 2	Strong positivity	4,4 %
	(804) Ventana PATHWAY anti-HER-2/neu		Negative (1)	2,2 %
		>>> 20	Weak positivity	44 %
		> 1	Strong positivity	2,2 %
	(999) another manufacturer	>>> 1	Weak positivity	2,2 %
Total per sample: n = 45 Success: 98 %				
Total success: 98 %				
(616) D1 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>> 10	Negative (0)	22 %
		> 1	Negative (1)	2,2 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 9	Negative (0)	20 %
		> 2	Negative (1)	4,4 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>> 22	Negative (0)	49 %
	(999) another manufacturer	>>> 1	Negative (0)	2,2 %
Total per sample: n = 45 Success: 100 %				
Total success: 100 %				
(617) D2 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>> 7	Negative (0)	16 %
		> 4	Negative (1)	8,9 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 4	Negative (0)	8,9 %
		> 7	Negative (1)	16 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>> 15	Negative (0)	33 %
		> 7	Negative (1)	16 %
	(999) another manufacturer	>>> 1	Negative (0)	2,2 %
Total per sample: n = 45 Success: 100 %				
Total success: 100 %				
(618) D3 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>> 5	Negative (0)	11 %
		> 6	Negative (1)	13 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 5	Negative (0)	11 %
		> 5	Negative (1)	11 %
			Weak positivity	2,2 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>> 15	Negative (0)	33 %
		> 7	Negative (1)	16 %
	(999) another manufacturer	>>> 1	Negative (0)	2,2 %
Total per sample: n = 45 Success: 98 %				
Total success: 98 %				
(621) E1 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>> 11	Strong positivity	24 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 11	Strong positivity	24 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>> 22	Strong positivity	49 %
	(999) another manufacturer	>>> 1	Strong positivity	2,2 %
Total per sample: n = 45 Success: 100 %				
Total success: 100 %				
(622) E2 expression HER-2/neu				
Slide	(802) Dako HercepTest		Negative (1)	4,4 %
		>>> 9	Weak positivity	20 %
	(803) Dako c-erbB-2 Onkoprotein		Negative (1)	4,4 %
		>>> 9	Weak positivity	20 %
	(804) Ventana PATHWAY anti-HER-2/neu		Negative (1)	8,9 %
		>>> 18	Weak positivity	40 %
	(999) another manufacturer	>>> 1	Weak positivity	2,2 %
Total per sample: n = 45 Success: 82 %				
Total success: 82 %				

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC2/17 - Immunohistochemistry - Detection of HER-2/neu

Dead line: 05.12.2017

Test

Sample	Group	N	Result	N _{rel}
(623) E3 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>> 11	Negative (0)	24 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 11	Negative (0)	24 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>> 22	Negative (0)	49 %
	(999) another manufacturer	>>> 1	Negative (0)	2,2 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				
(651) A1 sample staining				
Slide	(0) not specified	> 1	8 points	2,2 %
		> 1	12 points	2,2 %
		>>> 43	15 points	96 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				
(652) A2 sample staining				
Slide	(0) not specified	>>> 45	15 points	100 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				
(653) A3 sample staining				
Slide	(0) not specified	> 2	9 points	4,4 %
		>>> 1	14 points	2,2 %
		>>> 42	15 points	93 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				
(656) B1 sample staining				
Slide	(0) not specified	>>> 45	15 points	100 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				
(657) B2 sample staining				
Slide	(0) not specified	> 1	8 points	2,2 %
		> 3	12 points	6,7 %
		>>> 1	13 points	2,2 %
		>>> 1	14 points	2,2 %
		>>> 39	15 points	87 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				
(658) B3 sample staining				
Slide	(0) not specified	> 2	12 points	4,4 %
		>>> 43	15 points	96 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				
(661) C1 sample staining				
Slide	(0) not specified	>>> 1	13 points	2,2 %
		>>> 44	15 points	98 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				
(662) C2 sample staining				
Slide	(0) not specified	>>> 2	14 points	4,4 %
		>>> 43	15 points	96 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				
(663) C3 sample staining				
Slide	(0) not specified	1	7 points	2,2 %
		> 1	12 points	2,2 %
		>>> 1	13 points	2,2 %
		>>> 42	15 points	93 %
Total per sample: n = 45		Success: 98 %		
Total success: 98 %				
(666) D1 sample staining				
Slide	(0) not specified	>>> 45	15 points	100 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				
(667) D2 sample staining				
Slide	(0) not specified	1	6 points	2,2 %
		>>> 1	14 points	2,2 %
		>>> 43	15 points	96 %
Total per sample: n = 45		Success: 98 %		

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC2/17 - Immunohistochemistry - Detection of HER-2/neu

Dead line: 05.12.2017

Test

Sample	Group	N	Result	N _{rel}
Total success: 98 %				
(668) D3 sample staining				
Slide	(0) not specified	1	6 points	2,2 %
		>	2 8 points	4,4 %
		>>>	42 15 points	93 %
Total per sample: n = 45		Success: 98 %		
Total success: 98 %				
(671) E1 sample staining				
Slide	(0) not specified	>	1 10 points	2,2 %
		>	1 12 points	2,2 %
		>>>	43 15 points	96 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				
(672) E2 sample staining				
Slide	(0) not specified	1	7 points	2,2 %
		>	1 9 points	2,2 %
		>	1 11 points	2,2 %
		>>>	42 15 points	93 %
Total per sample: n = 45		Success: 98 %		
Total success: 98 %				
(673) E3 sample staining				
Slide	(0) not specified	>>>	45 15 points	100 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				
(681) IQC				
Slide	(0) not specified	5	0 points (unacceptable result)	11 %
		8	3 points (unacceptable result)	18 %
		>	9 6 points (acceptable result)	20 %
		>>>	1 8 points (excellent result)	2,2 %
		>>>	22 9 points (excellent result)	49 %
Total per sample: n = 45		Success: 71 %		
Total success: 71 %				

st_kl

End of report

Printed: 26.12.2017